Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24K Buy
258
+3
+1% +$266 ﹤0.01% 1532
2025
Q4
$20.5K Buy
255
+1
+0.4% +$84 ﹤0.01% 1558
2025
Q3
$24.8K Sell
254
-8
-3% -$644 ﹤0.01% 1379
2025
Q2
$18.3K Buy
+262
New +$14.9K ﹤0.01% 1405
2025
Q1
Sell
-212
Closed -$14.8K 2106
2024
Q4
$14.8K Sell
212
-68
-24% -$5.65K ﹤0.01% 1358
2024
Q3
$29.4K Buy
280
+27
+11% +$3.16K ﹤0.01% 1060
2024
Q2
$36K Buy
253
+11
+5% +$1.27K ﹤0.01% 900
2024
Q1
$27K Buy
242
+14
+6% +$1.67K ﹤0.01% 981
2023
Q4
$29.6K Sell
228
-149
-40% -$20.5K ﹤0.01% 946
2023
Q3
$61.5K Hold
377
﹤0.01% 785
2023
Q2
$69.1K Buy
377
+229
+155% +$33K ﹤0.01% 781
2023
Q1
$19.7K Hold
148
﹤0.01% 1092
2022
Q4
$12K Sell
148
-40
-21% -$2.82K ﹤0.01% 1231
2022
Q3
$11K Sell
188
-7
-4% -$452 ﹤0.01% 1270
2022
Q2
$11K Sell
195
-1
-0.5% -$58 ﹤0.01% 1352
2022
Q1
$15K Buy
+196
New +$13.4K ﹤0.01% 1335

Other funds holding ACLS

UMB Bank's ACLS Position: Q1 2026 in Review

UMB Bank increased its Axcelis (ACLS) stake by 1.2% in Q1 2026, buying an estimated $266 and bringing the position to 258 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #1532.

UMB Bank first reported a position in ACLS in Q1 2022 and has held it in 16 quarters since. The position peaked at $69.1K in Q2 2023. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.

  • UMB Bank held 258 shares of Axcelis worth $24K as of Q1 2026.
  • UMB Bank bought 3 Axcelis shares in Q1 2026, an estimated $266.
  • Axcelis made up ﹤0.01% of UMB Bank's portfolio in Q1 2026, its #1532 holding.
  • UMB Bank first reported a position in Axcelis in Q1 2022 and has held it in 16 quarters since.
  • UMB Bank's Axcelis position peaked at $69.1K in Q2 2023.
  • 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.

Based on UMB Bank's 13F filing for Q1 2026, filed 11 May 2026.